House
GuidelinesCalculatorsPricingBlog
Ask House ↗
Guidelines↗Calculators↗Pricing↗Blog↗
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
Back to guidelines
Endocrinology

Hyperparathyroidism (primary): diagnosis, assessment and initial management

NICE · 2019 edition / updateSource checked 29 October 2026
Read the source publication
House clinical summary

Scope

This is the NICE guideline NG132 on primary hyperparathyroidism. It covers when to check albumin-adjusted serum calcium in primary care and how to interpret repeat calcium and parathyroid hormone (PTH) results. It also covers secondary-care confirmation and work-up, including vitamin D, exclusion of familial hypocalciuric hypercalcaemia, and baseline bone and renal assessment. Other topics are referral for parathyroid surgery, preoperative localisation imaging, choice of operation, postoperative follow-up and management after failed surgery. The guideline also addresses non-surgical options (cinacalcet, bisphosphonates), long-term monitoring, care around and during pregnancy, and patient information. Recommendation strength is expressed through NICE wording such as offer, consider and do not.

Written by House with AI assistance · AI-assisted source check 29 October 2026.

This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.

Diagnostic testing in primary care

  • Check albumin-adjusted serum calcium when any of these possible pointers to primary hyperparathyroidism is present: - hypercalcaemic symptoms such as thirst, frequent or excessive urination, or constipation - osteoporosis or a previous fragility fracture - a renal stone - an incidental albumin-adjusted calcium of 2.6 mmol/litre or above [1]
  • Calcium testing may be considered for people with chronic non-differentiated symptoms. These are long-term symptoms with several possible causes, such as fatigue, mild confusion, musculoskeletal pain, mood disturbance, insomnia, frequent urination, increased thirst and digestive problems. [1]
  • Ionised calcium should not be measured when testing for primary hyperparathyroidism. [1]
  • Repeat albumin-adjusted calcium at least once in either situation: - the first value is 2.6 mmol/litre or above - the first value is 2.5 mmol/litre or above and features of primary hyperparathyroidism are present Whether to repeat further depends on the calcium level and the person's symptoms. [1]
  • Measure PTH in either situation: - albumin-adjusted calcium is 2.6 mmol/litre or above on at least 2 separate occasions - calcium is 2.5 mmol/litre or above on at least 2 separate occasions and the condition is suspected Use a random sample, with calcium measured concurrently. PTH should not be routinely repeated in primary care. [1]
  • Seek specialist advice in either situation: - PTH is above the midpoint of the reference range and primary hyperparathyroidism is suspected - PTH is below the midpoint with concurrent calcium of 2.6 mmol/litre or above Specialist advice may be a referral or a telephone call. [1]
  • No further hyperparathyroidism investigations are advised when both of these apply: - PTH is within the reference range but below its midpoint - concurrent calcium is below 2.6 mmol/litre If PTH is below the lower limit of the reference range, look for other diagnoses, including malignancy. [1]

Secondary care assessment and surgical referral

  • When the diagnosis is probable, check vitamin D and offer supplementation if needed. [1]
  • To distinguish primary hyperparathyroidism from familial hypocalciuric hypercalcaemia, assess urinary calcium excretion using any one of: - a 24-hour urine collection - a random renal calcium:creatinine excretion ratio - a random calcium:creatinine clearance ratio [1]
  • Once the diagnosis is confirmed: - assess symptoms and comorbidities - measure eGFR or serum creatinine - arrange DXA of the lumbar spine, distal radius and hip - arrange renal tract ultrasound [1]
  • Refer confirmed cases to a parathyroid surgeon if any of these is present: - hypercalcaemic symptoms - end-organ disease (renal stones, fragility fractures or osteoporosis) - albumin-adjusted calcium of 2.85 mmol/litre or above Referral may also be considered for confirmed cases without these features. [1]

Surgical management

  • Preoperative imaging: - Offer first-line imaging, usually ultrasound, if it will inform the surgical approach. - A second modality, usually sestamibi, may be considered if it would further guide surgery. - Do not add more imaging if both modalities fail to find an adenoma or disagree. Surgery should still go ahead, performed by a surgeon expert in four-gland exploration, even if no adenoma is localised. Refer ectopic adenomas to a centre with relevant expertise. [1]
  • When imaging shows a single adenoma in the neck, offer a choice of four-gland exploration or focused parathyroidectomy. Discuss each option's procedure, effectiveness, anaesthesia, likely duration, scar size and risks. [1]
  • Offer four-gland exploration when imaging does not identify a single adenoma. Consider it when first- and second-modality scans are discordant. [1]
  • Intraoperative PTH monitoring should not be used in first-time parathyroid surgery. [1]
  • After surgery: - Before discharge, measure calcium and PTH as a baseline. - Recheck calcium 3 to 6 months later to judge success. - If calcium is then within the reference range, regard surgery as successful and monitor calcium once a year. [1]
  • After unsuccessful surgery, hold a specialist-centre MDT review covering: - the initial operative findings - previous imaging and histology - the clinical and biochemical indications for reoperation Also offer monitoring. Any repeat surgery should be done at a centre experienced in reoperative parathyroid surgery. [1]

Non-surgical management

  • Cinacalcet may be considered when surgery has failed, is unsuitable or has been declined, and calcium meets either threshold: - 2.85 mmol/litre or above with hypercalcaemic symptoms - 3.0 mmol/litre or above regardless of symptoms Decisions to continue depend on response: - in the symptomatic 2.85 group, on symptom improvement - in the 3.0 group, on improvement in either symptoms or calcium In May 2019, use after unsuccessful surgery was off label. [1]
  • A bisphosphonate may be considered to lower fracture risk in people with increased fracture risk. Bisphosphonates should not be offered to treat the chronic hypercalcaemia itself. [1]

Monitoring

  • Offer monitoring to everyone diagnosed, as set out in table 1. After successful surgery: - measure calcium once a year - for coexisting osteoporosis or renal stones, seek specialist opinion on monitoring via local pathways After multigland surgery, or with recurrence after successful surgery, seek specialist endocrine opinion. For all patients, assess cardiovascular and fracture risk in line with NICE guidance. [1]
  • Without surgery, or after unsuccessful surgery: - Measure calcium and eGFR or creatinine yearly, unless the person takes cinacalcet; then follow the product characteristics. If these results raise concerns, repeat the calcium measurement as advised in the calcium-testing section. - DXA may be considered at diagnosis and every 2 to 3 years. - Offer renal tract ultrasound at diagnosis, at presentation and when a stone is suspected. If DXA or renal ultrasound results raise concerns, follow the recommendation on referral for surgery. [1]

Pregnancy

  • Offer parathyroid surgery to women with primary hyperparathyroidism who are considering pregnancy. In pregnancy: - discuss management with a specialist-centre MDT and refer for specialist care if needed - the specified MDT membership includes, among others, an obstetrician, a physician with relevant expertise and an anaesthetist - consult the MDT about monitoring [1]
  • Neither cinacalcet nor bisphosphonates should be offered in pregnancy. Clinicians should be aware of the increased risk of hypertensive disease in pregnancy for these women. [1]

Information and support

  • Patients should receive: - information about the condition and about available surgical and non-surgical treatments, including their benefits and drawbacks - practical advice on reducing symptoms and preparing for treatment, including recovery and return to work - an explanation of the type, frequency and purpose of ongoing monitoring [1]

Limitations and use

  • Summary is based only on the recommendations chapter. Research recommendations, rationale and impact sections, and the underlying evidence reviews were not available.
  • Flowcharts and visual algorithms were represented only by alternative text and were not reviewed.
  • Several recommendations defer to other NICE guidelines that are not covered here, including those on osteoporosis, renal and ureteric stones, hypertension in pregnancy, cardiovascular disease and patient experience.
  • The guideline gives no drug dosing. Cinacalcet monitoring defers to the summary of product characteristics, and the off-label status of cinacalcet is stated as of May 2019.
  • Detailed monitoring in pregnancy, after multigland disease, or with recurrence after successful surgery is deferred to specialist or MDT opinion.

This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.

Summary sources

  1. 1
    Hyperparathyroidism (primary): diagnosis, assessment and initial management

    Guideline recommendation text consulted

Original guideline

Publication details

Issuing organisation
NICE
First published
23 May 2019
Resource type
Clinical guideline · House clinical summary

The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.

On this page

  • Scope
  • Diagnostic testing in primary care
  • Secondary care assessment and surgical referral
  • Surgical management
  • Non-surgical management
  • Monitoring
  • Pregnancy
  • Information and support
  • Limitations and use
  • Summary sources
  • Publication details
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House